GH Deficiency (GHD), Growth Retardation
Conditions
Keywords
children
Brief summary
The primary objective of this study is to compare the pharmacokinetic and pharmacodynamic effect between two preparations of somatropin (T and C) after a single administration of 5 mg in healthy subjects by altering serum somatropin pharmacokinetic parameters (AUC0-24h, AUC0-inf, Cmax, Tmax and T1 / 2) and pharmacodynamic (measurement of serum levels of IGF-1 presented by the concentration-time profile, AUC 0-24h and AUC0-inf.).
Detailed description
Secondly, the investigators will observe the clinical safety and tolerability after single dose administration in subjects, by comparing clinical parameters and the incidence of adverse events between groups.
Interventions
DRUGSomatropin
single subcutaneous dose of 5mg
Sponsors
Azidus Brasil
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 32 Years
Healthy volunteers
Yes
Inclusion criteria
1. Research subjects who agree with all study procedures, sign and date, of their own free will, the IC; 2. Research subjects were male, aged between 18 and 32 years; 3. Research subjects with body mass index greater than or equal to 20 and less than or equal to 25; 4. Considered healthy subjects, both clinical and laboratory.
Exclusion criteria
1. Have donated or lost 450 mL or more blood in the 6 months preceding the study; 2. Having participated in any experimental study or have taken any experimental drug in the 12 months preceding the start of the study; 3. Having made use of regular medication less than two weeks to interfere with the pharmacokinetics / pharmacodynamics of the drug under study, such as glucocorticoids, anabolic steroids, androgens, estrogens and thyroid hormones; 4. Present history of alcohol abuse, drug or drugs; 5. Have a history of liver disease, renal, pulmonary, gastrointestinal, hematologic, or psychiatric; 6. Have made previous use of somatropin; 7. Make use of energy supplements and / or be frequent consumers of soy products (eg replacement of animal milk for soy milk).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The primary efficacy endpoint will be based in the investigation of pharmacokinetics and pharmacodynamics of somatropin in research subjects after administration of single dose, sc, of the drug. | PK: 0, 1, 2, 3, 3:30, 4, 4:30, 5, 6, 9, 12, 15, 18, 24 hours. PD: 0, 6, 12, 24 hours. | Pharmacokinetic evaluation will be based on data obtained from the average dosage of somatropin plasma. Thus, the time of collection facilities provide the pharmacokinetic parameters AUC0-24h, AUC0-inf, Cmax, Tmax and T1 / 2, which will be compared between the two formulations. The quantification of serum somatropin kit will be performed by ELISA validated using human serum as a biological matrix. The evaluation of the pharmacodynamics will be performed by quantifying serum levels of IGF-1 presented by the concentration-time profile, AUC 0-24h and AUC0-inf. |
Secondary
| Measure | Time frame |
|---|---|
| After administration of the drug will be evaluated for safety and tolerability of the drug through the presence of hematoma, pain, itching and local redness, as well as the incidence of adverse events directly related to somatropin. | 15 weeks |
Countries
Brazil
Contacts
Primary ContactAlexandre Frederico, physian
Outcome results
None listed